Abstract
Sepsis is an acute and severe disease associated with early and late high mortality, high and growing prevalence, and impressive costs. In October 2002, during the European Society of Intensive Care Medicine annual congress, the Surviving Sepsis Campaign was launched through a "Barcelona Declaration" - a document calling critical care providers, governments, health agencies and lay people to join the fight against sepsis. The aim of the campaign was to reduce the sepsis mortality rate by 25% within 5 years (actually, this deadline has been ended from 2007 to 2009). In 2003, a group of international critical care and infectious disease experts in the diagnosis and management of infection and sepsis met to develop guidelines that the bedside clinician could use to improve the outcome of severe sepsis and septic shock. A comprehensive document created from the committees deliberations was published in prestigious journals. Thus, the SSC is a global, multi-organizational initiative to fight sepsis and undoubtedly, this campaign is a historic step for critical care medicine. This paper highlights the recommendations and the strategies proposed by SSC to implement them in intensive care units.
Keywords: septic shock, Vasopressors, Recombinant Human Activated Protein, Sepsis Campaign screening, Inotropic Therapy, Steroids
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory
Volume: 6 Issue: 2
Author(s): Eliezer Silva, Nelson Akamine, Reinaldo Salomao, Sean R. Townsend, Richard P. Dellinger and Mitchell Levy
Affiliation:
Keywords: septic shock, Vasopressors, Recombinant Human Activated Protein, Sepsis Campaign screening, Inotropic Therapy, Steroids
Abstract: Sepsis is an acute and severe disease associated with early and late high mortality, high and growing prevalence, and impressive costs. In October 2002, during the European Society of Intensive Care Medicine annual congress, the Surviving Sepsis Campaign was launched through a "Barcelona Declaration" - a document calling critical care providers, governments, health agencies and lay people to join the fight against sepsis. The aim of the campaign was to reduce the sepsis mortality rate by 25% within 5 years (actually, this deadline has been ended from 2007 to 2009). In 2003, a group of international critical care and infectious disease experts in the diagnosis and management of infection and sepsis met to develop guidelines that the bedside clinician could use to improve the outcome of severe sepsis and septic shock. A comprehensive document created from the committees deliberations was published in prestigious journals. Thus, the SSC is a global, multi-organizational initiative to fight sepsis and undoubtedly, this campaign is a historic step for critical care medicine. This paper highlights the recommendations and the strategies proposed by SSC to implement them in intensive care units.
Export Options
About this article
Cite this article as:
Silva Eliezer, Akamine Nelson, Salomao Reinaldo, Townsend R. Sean, Dellinger P. Richard and Levy Mitchell, Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187153006777442378
DOI https://dx.doi.org/10.2174/187153006777442378 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta- Analysis of Randomized Trials
Current Vascular Pharmacology Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies
Current Molecular Pharmacology Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Current Vascular Pharmacology Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials The Hellp Syndrome: A Review
Current Women`s Health Reviews Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Blood Pressure Control in Cardiovascular Prevention
Current Pharmaceutical Design Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry